BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 29, 2026
Home » Authors » David Ho

David Ho

Articles

ARTICLES

An unconventional model: Caywon taking advantage of Crowd Machine platform

Dec. 27, 2017
By David Ho
HONG KONG – Caywon Pharmaceutical Group Ltd. is using Crowd Machine technology to become one of the first companies in China to specialize in decentralizing the pharmaceuticals development process.
Read More

An unconventional model: Caywon taking advantage of Crowd Machine platform

Dec. 22, 2017
By David Ho
HONG KONG – Caywon Pharmaceutical Group Ltd. is using Crowd Machine technology to become one of the first companies in China to specialize in decentralizing the pharmaceuticals development process.
Read More

Transenterix signs $29M deal for surgical robot asset commercialization in China

Dec. 21, 2017
By David Ho

Korea tightens regulations for med-tech industry, eases requirements for biotech

Dec. 20, 2017
By David Ho

Advent Access raises $2M in largest pre-series A financing for SEA med-tech firm

Dec. 14, 2017
By David Ho

Sanofi's Dengvaxia faces legal threat, investigations after Philippines suspension

Dec. 13, 2017
By David Ho
HONG KONG – Controversy has continued to mount in the Philippines around Sanofi Pasteur Ltd.'s dengue vaccine, Dengvaxia, which is now facing questions about its effectiveness and the manner and speed with which the government adopted it in its national vaccination program.
Read More

Sanofi's Dengvaxia faces legal threat, investigations after Philippines suspension

Dec. 13, 2017
By David Ho
HONG KONG – Controversy has continued to mount in the Philippines around Sanofi Pasteur Ltd.'s dengue vaccine, Dengvaxia, which is now facing questions about its effectiveness and the manner and speed with which the government adopted it in its national vaccination program.
Read More

Singapore's Kronikare developing AI system for chronic wound assessment

Dec. 11, 2017
By David Ho

GE Healthcare signs deal to develop first-in-market tech for ultrasound devices

Dec. 6, 2017
By David Ho

Astrazeneca, Chinese Future Industry Investment Fund launch JV for novel drugs

Dec. 6, 2017
By David Ho
HONG KONG – Astrazeneca plc has teamed up with the Chinese Future Industry Investment Fund (FIIF) to form a joint venture in China for drug development via an equally owned, stand-alone company named Dizal Pharmaceutical.
Read More
View All Articles by David Ho

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing